ARB rhabdomyolysis labeling
Executive Summary
All seven angiotensin II receptor blocker manufacturers have either added class labeling for rhabdomyolysis risk or are currently updating labeling, FDA said March 10. One manufacturer had put the labeling update on hold pending receipt of additional background information from FDA (1"The Pink Sheet" March 7, 2004, p. 14)...